SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE
13A-16 OR 15D-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
December, 2023
Commission File
Number 1-15182
DR.
REDDY’S LABORATORIES LIMITED
(Translation of registrant’s name into English)
8-2-337, Road No. 3, Banjara Hills
Hyderabad, Telangana 500 034, India
+91-40-49002900
(Address of principal executive office)
Indicate by check mark whether the registrant files
or will file annual reports under cover of Form 20-F or Form 40-F.
Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ______
Note: Regulation S-T Rule 101(b)(1) only permits
the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______
Note: Regulation S-T Rule 101(b)(7) only permits
the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must
furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the
registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities
are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the
registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other
Commission filing on EDGAR.
Indicate by check mark whether by furnishing the information
contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
If “Yes” is marked, indicate below the
file number assigned to registrant in connection with Rule 12g3-2(b): 82-________.
EXHIBITS
SIGNATURES
Pursuant to the requirements of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
DR. REDDY’S LABORATORIES LIMITED
(Registrant) |
|
|
Date: December 29, 2023 |
By: |
/s/ K Randhir Singh |
|
|
Name: |
K Randhir Singh |
|
|
Title: |
Company Secretary |
Exhibit 99.1
|
Dr. Reddy’s Laboratories Ltd.
8-2-337, Road No. 3, Banjara Hills,
Hyderabad - 500 034, Telangana,
India.
CIN : L85195TG1984PLC004507
Tel : +91 40 4900 2900
Fax : +91 40 4900 2999
Email : mail@drreddys.com
www.drreddys.com |
December 29, 2023
National Stock Exchange of India Ltd. (Scrip Code:
DRREDDY-EQ)
BSE Limited (Scrip Code: 500124)
New York Stock Exchange Inc. (Stock Code: RDY)
NSE IFSC Ltd. (Stock Code: DRREDDY)
Dear Sir/Madam,
| Ref: | Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations,
2015 (“SEBI Listing Regulations”) |
| Sub: | Appointment of Mr. Sanjiv Mehta as an Independent Director |
Pursuant to Regulation 30 of the SEBI (Listing Obligations
and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), we would like to inform that Mr. Sanjiv Mehta
(DIN: 06699923) has been appointed as an Additional Director, categorized as Independent, on the Board of the Company, for a term of five
consecutive years, effective from December 29, 2023.
The appointment of Mr. Mehta is approved by the Board
of Directors of the Company, by way of Circular Resolution passed today, i.e. December 29, 2023, based on recommendations of the Nomination,
Governance and Compensation Committee and is subject to approval of shareholders through Postal Ballot process. The profile of Mr. Mehta
is enclosed with this intimation.
Mr. Mehta is not related to any of the Directors or
Key Managerial Personnel of the Company and is not debarred from holding the office of Director by virtue of any SEBI order or any other
such authority. He meets the criteria for being appointed as an Independent Director under the statutes applicable to the Company.
The details required under Regulation 30 of the SEBI
Listing Regulations, read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, with respect to the above appointment
is given in Annexure enclosed herewith.
This is for your information and records.
Thanking you,
Yours faithfully,
For Dr. Reddy’s Laboratories Limited
K Randhir Singh
Company Secretary, Compliance Officer & Head-CSR
Encl: as above
Annexure
Details under Regulation 30 of SEBI Listing Regulations,
read with SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023
Sl. No. |
Particulars |
Details |
1 |
Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise |
Appointment |
2 |
Date of appointment/ re-appointment/ cessation (as applicable); and term of appointment/ re-appointment |
December 29, 2023
Appointment by the Board of Directors on December
29, 2023, as an Additional Director, categorized as Independent, for a term of five consecutive years, with effect from December 29, 2023,
to December 28, 2028.
The said appointment is subject to approval of the
shareholders of the Company through Postal Ballot process. |
3 |
Brief profile (in case of appointment) |
Enclosed with this intimation |
4 |
Disclosure of relationships between directors (in case of appointment of a director) |
Mr. Sanjiv Mehta is not related to any of the Directors or Key Managerial Personnel of the Company. |
Profile of Mr. Sanjiv Mehta
|
Mr. Sanjiv Mehta has been the Chairman/ CEO and Managing Director (2013-23) of Hindustan Unilever Limited (HUL) which is India’s foremost Fast-Moving Consumer Goods (FMCG) Company. During his 10 years at the helm of Hindustan Unilever, the market capitalization of the Company increased from $17 billion to $76 billion making it the fifth most valuable company in India and the most valuable business for Unilever. Mr. Mehta was also the President of Unilever South Asia having a combined turnover of $9 billion and member of ‘Unilever Leadership Executive’, the global executive board of the consumer goods giant. |
At present, Mr. Mehta is the Board Member (Non-Executive)
of Air India & Danone, France and is the President Commissioner (Non-Executive Chairman) of Unilever Indonesia.
Mr. Mehta was the CEO/ Executive Chairman of Unilever
Businesses in different parts of the world for 21 years from 2002-23. He was Chairman and Managing Director of Unilever Bangladesh Limited
(2002-06), Chairman and CEO of Unilever Philippines Inc. (2007-08), Chairman of Unilever - North Africa and Middle East (2008-13) and
took over India and South Asia responsibilities from 2013. In each of these roles he left his imprint by turning around businesses in
trouble, winning major competitive battles and accelerating growth.
Mr. Mehta has done his Bachelor’s in Commerce,
Chartered Accountancy and has also completed his Advanced Management Program (Harvard Business School). Mr. Mehta has been the President
of India’s oldest and largest trade body FICCI (Federation of Indian Chambers of Commerce and Industry) during 2021-22, is a member
of the South Asia Advisory Board of Harvard Business School and is Chairman Emeritus of ‘Vikaasa’, a coalition of top Indian
and MNC companies.
During the period when Mr. Mehta was heading HUL it
won several recognitions including the prestigious The Economic Times ‘Company of the Year’ & ‘Corporate Citizen
of the Year’ awards, Business Standard’s ‘Company of the year’ award, the ‘Best Governed Company’
award by the Asian Centre for Corporate Governance and Sustainability and the ‘Outstanding Company of the Year’ award at CNBC-TV18’s
India Business Leader Awards (IBLA). Forbes rated HUL as the most innovative company in India and the 8th most innovative company in the
world. Aon Hewitt in a global study rated HUL as the 3rd best company globally for building leaders.
Mr. Mehta was conferred the honorary degree of ‘Doctor
of Philosophy in Business Management’ by Xavier University (Xavier Institute of Management) in 2019. He has received several personal
recognitions including the ‘Best CEO Multinational’ by Forbes, the ‘Management Man of the Year’ by Bombay
Management Association, the ‘CA Business Leader’ by The Institute of Chartered Accountants of India, the ‘Best Transformational
Leader’ by the Asian Centre for Corporate Governance and Sustainability, the ‘Business Leader of the Year’ by The Economic
Times, ‘Best CEO’ Award from Business Today, Pralhad P. Chhabria Memorial Global Award, the ‘JRD Tata Corporate
Leadership award’ by the All India Management Association, the ’Sir Jehangir Ghandy Medal’ by Xavier School of Management
(XLRI), Jamshedpur, ‘IMPACT Person of the Year’ by exchange4media group (Business World), ‘Lifetime Achievement
Award’ by CEO’s Association for Inclusive India -SKOCH Group, ‘CEO of the year’ by Business Standard and
‘Best of the Best CEO’s’ by Fortune. He has also been inducted into the ‘Hall of Fame’ by The Institute
of Chartered Accountants of India.
Dr Reddys Laboratories (NYSE:RDY)
Historical Stock Chart
From Apr 2024 to May 2024
Dr Reddys Laboratories (NYSE:RDY)
Historical Stock Chart
From May 2023 to May 2024